Alira Health Announces its Role as Strategic Advisor to Naxicap

News
Published on:
July 21, 2021
Written by:
jean-louis simon

Alira Health is proud to announce its role as strategic advisor to Naxicap in the equity investment in Ceres Pharma Bv.

The Alira Health strategic, commercial, and regulatory due diligence teams brought their expertise and market insights to analyze the diversified product portfolio of Ceres and the various geographies it is operating in.

 

“We are pleased that Naxicap was able to become the new significant shareholder of Ceres and that Alira Health was part of the effort. The opportunities for Ceres going forward are tremendous and the growth both in Benelux and in Central Europe will certainly be significant,” said Jean-Louis Simon, Senior Partner, Alira Health.

 

Read the full press release here.

Related news

Pharma
Events October 13, 2021
Event: World Drug Safety Congress
Join our team of experts at World Drug Safety Congress in Boston, MA.
Pharma
Events October 1, 2021
Event: Meeting on the Mesa
Join us at Meeting on the Mesa in Carlsbad, CA on October 11-14, 2021.
Due Diligence Research & Development
Publications August 18, 2021
Infographic: Indication Prioritization and Pre-Commercial Value Assessment
Download our infographic on Indication Prioritization and Pre-Commercial Value Assessment.
Pharma Research & Development
Publications August 2, 2021
Infographic: Prioritization Strategy of R&D Targets for Biotech Company
Download our infographic on Prioritization Strategy of R&D Targets for Biotech Company
Due Diligence MedTech Patient Engagement Pharma
Multimedia April 12, 2021
Evolution of the Drug Delivery Systems Industry and its Increasing Role in Driving Patient Outcomes
In the third episode, Amira Ghozali, Aptar Pharma, Kenny Carberry, and Aude Ouensanga, discuss the evolution of the DDS industry, its relationship with Pharma, and its increasing role(...)
M&A MedTech Pharma
News April 12, 2021
Alira Health Strengthens its Growth Strategy with a $35M Funding, led by Creadev
Alira Health strengthens its growth strategy with a $35M funding, led by Creadev.
Due Diligence MedTech Patient Engagement
Publications March 24, 2021
Drug Delivery Devices (DDD): Increasing Role in Patient Outcome and Future Trends, New England’s Global Appeal to Foster Collaboration
Download our newest report, Drug Delivery Devices (DDD): Increasing role in patient outcome and future trends, New England’s global appeal to foster collaboration. In this report,(...)

Our locations around the globe

Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.